Kwality Pharmaceuticals surges on getting approval from Brazil's ANVISA
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Kwality Pharmaceuticals is currently trading at Rs. 394.15, up by 24.55 points or 6.64% from its previous closing of Rs. 369.60 on the BSE.
The scrip opened at Rs. 398.00 and has touched a high and low of Rs. 404.00 and Rs. 376.05 respectively. So far 26168 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 961.50 on 03-Jan-2022 and a 52 week low of Rs. 265.60 on 08-Aug-2022.
Last one week high and low of the scrip stood at Rs. 404.00 and Rs. 355.00 respectively. The current market cap of the company is Rs. 403.69 crore.
The promoters holding in the company stood at 54.45%, while Non-Institutions held 45.55% stake in the company.
Kwality Pharmaceuticals has received approval from Brazil's National Health Surveillance Agency ANVISA (Agencia Nacional de Vigilancia Sanitaria) for its Injectable formulations manufacturing unit at Amritsar along with Oncology Injectable unit at Himachal Pradesh.
The approval grants access to the Company to register and market its products at the large and growing Brazilian Pharmaceutical Market. The ANVISA approved facility is capable to manufacture liquid injection (in form of Ampoule and vials) and lyophilized formulation (vials).
Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company. It is engaged in manufacturing finished pharmaceutical formulations in dosage form.
